JenaValve Technology has raised $4.9 million in a new round of debt financing, according to an SEC filing posted this week.
The Irvine, Calif.-based company is one of several smaller players looking to enter the transcatheter aortic valve implant space as it challenges major players Edwards Lifesciences (NYSE:EW), Medtronic (NYSE:MDT), Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX).
JenaValve has not yet stated how it plans to spend funds raised in the round, but is not seeking any more funds.
Money in the round comes from 11 anonymous sources, with the first sale recorded on Jan. 23, according to the filing.
